Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy?

In This Article:

Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability to pick winning stocks. This year hedge funds' top 20 stock picks easily bested the broader market, at 18.7% compared to 12.1%, despite there being a few duds in there like Berkshire Hathaway (even their collective wisdom isn't perfect). The results show that there is plenty of merit to imitating the collective wisdom of top investors.

SAGE Therapeutics Inc (NASDAQ:SAGE) investors should pay attention to a decrease in hedge fund interest of late. Our calculations also showed that sage isn't among the 30 most popular stocks among hedge funds.

According to most shareholders, hedge funds are perceived as worthless, old financial tools of yesteryear. While there are more than 8000 funds in operation today, Our experts choose to focus on the top tier of this club, about 750 funds. These hedge fund managers command the majority of all hedge funds' total asset base, and by paying attention to their matchless equity investments, Insider Monkey has unearthed several investment strategies that have historically outstripped the market. Insider Monkey's flagship hedge fund strategy outstripped the S&P 500 index by around 5 percentage points per year since its inception in May 2014 through the end of May. We were able to generate large returns even by identifying short candidates. Our portfolio of short stocks lost 30.9% since February 2017 (through May 30th) even though the market was up nearly 24% during the same period. We just shared a list of 5 short targets in our latest quarterly update and they are already down an average of 11.9% in less than a couple of weeks whereas our long picks outperformed the market by 2 percentage points in this volatile 2 week period.

Peter Kolchinsky
Peter Kolchinsky

Let's review the latest hedge fund action encompassing SAGE Therapeutics Inc (NASDAQ:SAGE).

How have hedgies been trading SAGE Therapeutics Inc (NASDAQ:SAGE)?

At Q1's end, a total of 28 of the hedge funds tracked by Insider Monkey were long this stock, a change of -3% from one quarter earlier. On the other hand, there were a total of 37 hedge funds with a bullish position in SAGE a year ago. So, let's check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.